<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375959</url>
  </required_header>
  <id_info>
    <org_study_id>2010-398</org_study_id>
    <nct_id>NCT01375959</nct_id>
  </id_info>
  <brief_title>Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance</brief_title>
  <acronym>RSV</acronym>
  <official_title>The Effect of Resveratrol in Older Adults With Impaired Glucose Tolerance: a Double-Blind Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resveratrol is a substance found in many plants, including grapes and red wine, which is
      widely used as a nutritional supplement. Studies in cells and lower animals show that
      resveratrol has many potential benefits, including prolonging lifespan, preventing cancer and
      heart disease and normalization of glucose metabolism. Although use of this agent shows great
      promise in the treatment and/or prevention of diabetes, there have been no studies reported
      to date in humans. As an initial step, this proposal is for a 6 week pilot study of
      resveratrol treatment in older adults with impaired glucose tolerance (IGT) in order to
      explore its effects on post-meal blood glucose metabolism. Preliminary studies will also be
      conducted to explore how resveratrol works by studying cellular function (in muscle samples
      obtained from study participants) and by testing resveratrol's effect on blood vessel
      function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post meal glucose area under the curve</measure>
    <time_frame>end of each of two 6 week treatment periods</time_frame>
    <description>Glucose AUC following a standard mixed meal challenge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>end of each of two 6 week treatment periods</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>resveratrol</intervention_name>
    <description>resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks</description>
    <arm_group_label>resveratrol</arm_group_label>
    <other_name>RevGenetics</other_name>
    <other_name>X500 Resveratrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 placebo capsules orally twice a day for 6 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  impaired glucose tolerance

        Exclusion Criteria:

          -  history of estrogen-dependent neoplasm

          -  use of certain drugs: high dose statins, warfarin, antiepileptics

          -  current treatment with anti-diabetes medications

          -  impaired liver or kidney function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Crandall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Migdalia Reid, RN, MPH</last_name>
    <phone>718-405-8271</phone>
    <email>migdalia.reid@einstein.yu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine of Yeshiva University</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>June 16, 2011</last_update_submitted>
  <last_update_submitted_qc>June 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jill Crandall MD</name_title>
    <organization>Albert Einstein College of Medicine of Yeshiva University</organization>
  </responsible_party>
  <keyword>resveratrol</keyword>
  <keyword>glucose intolerance</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 2, 2018</submitted>
    <returned>January 29, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

